Related Experiment Video
Updated: Jul 20, 2025

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.1K
Pre-training and ensembling based Alzheimer's disease detection.
Summary
Early Alzheimer's disease (AD) detection is crucial. A novel AI framework using audio and PET scans achieved 92% and 99% accuracy, outperforming existing methods for timely diagnosis.
Area of Science:
- Artificial Intelligence in Medicine
- Neuroimaging and Signal Processing
- Geriatric Health and Disease Detection
Background:
- Alzheimer's disease (AD) poses a significant health challenge for the elderly.
- Early diagnosis, particularly during the Mild Cognitive Impairment (MCI) phase, is critical due to limited effective treatments.
- Objective diagnostic tools are needed to support clinical decision-making.
Purpose of the Study:
- To develop an automated classification technology for Alzheimer's disease detection.
- To enhance Alzheimer's disease detection using artificial intelligence, aiming to reduce diagnostic costs.
- To evaluate a novel pre-trained ensemble-based AD detection (PEADD) framework.
Main Methods:
- Proposed a novel pre-trained ensemble-based AD detection (PEADD) framework utilizing ResNet, VGG, and EfficientNet base learners.
- Investigated context-enriched image modalities for audio-based AD detection and employed image denoising strategies.
- Implemented PET (Positron Emission Tomography)-based AD detection using denoised PET images and explored hard and soft voting ensemble methods.
Main Results:
- Achieved classification accuracies of 92% for audio-based and 99% for PET-based AD detection.
- The PEADD framework demonstrated superior performance compared to state-of-the-art methods on both datasets.
- Validated the effectiveness of context-enriched audio analysis and denoised PET imaging for AD detection.
Conclusions:
- The developed network model offers an objective basis for healthcare professionals in detecting Alzheimer's disease.
- The PEADD framework shows significant potential for improving early and accurate AD diagnosis.
Related Concept Videos
Alzheimer's Disease: Overview
521
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
521
Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215

